Phantom Neuro CEO Connor Glass to Present during BioFuture™ 2025

Austin-Headquartered Neurotech Maverick Reflects Upon Industry, Company Growth

NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Dr. Connor Glass, CEO and Founder of Phantom Neuro, the company delivering breakthrough advancements in human-machine interface, will be speaking on the mainstage of this year's BioFuture™ 2025. The conference is hosted by Demy-Colton and held in New York City this October 13th through 15th.

The innovative healthcare startup will be on stage among the likes of biotech, pharma, digital medicine, TechBio, healthcare delivery, policy, and investment leaders, participating in an industry-wide discussion of how new policy, technology, and capital markets are reshaping the healthcare ecosystem. Events will be held at Cure, a Deerfield affiliate in health and life science innovation.

Dr. Connor Glass , CEO and founder Phantom Neuro, will present during a Spotlight Panel, " Rewiring Minds: Breakthroughs in Brain & CNS Health" (Spotlight Panel 1B). More information:

• This panel will be held on Monday, October 13th, from 11:00 AM-12:00 PM
• It will be on the 12th Floor of Cure: 345 Park Ave S., New York, NY 10010

The panel will be moderated by Ginger Johnson, Senior Vice President, Lumanity. The panel includes:

• Connor Glass, CEO & Founder, Phantom Neuro
• Adam Rogers, CEO, NervGen Pharma
• Arun Swaminathan, CEO, Coya Therapeutics, Inc.
• Brent Vaughan, CEO & Founder, Eratos Therapeutics
• Beth Hoffman, CEO, Origami Therapeutics, Inc.

This year has shown robust and continued growth for Phantom Neuro, from the company receiving FDA Breakthrough Device and TAP Designations to announcing additional funding and a new strategic partner in European medical and industrial robotic technologies company, Ottobock.

More recently, Phantom Neuro published a peer-reviewed white paper detailing findings from the startup's proprietary Phantom X platform. This study demonstrates intuitive and functional prosthesis control designed for real-world use.

ABOUT PHANTOM NEURO
Phantom Neuro is a neurotechnology company developing a minimally invasive interface that enables intuitive control of prosthetic limbs and robotic exoskeletons. Originally developed at the Johns Hopkins University School of Medicine, Phantom Neuro has received funding from investors including Ottobock, Blackrock Neurotech, Breakout Ventures, Draper Associates, LionBird Ventures, and Time BioVentures. Headquartered in Austin, Texas, Phantom Neuro is backed by a globally recognized advisory board of experts from CTRL-Labs, D.A.R.P.A., Johns Hopkins University, and Precision Neuro. Learn more at www.phantomneuro.com.

CONTACT:
Shannon Wilsey, Public Relations | Phantom Neuro
[email protected]

SOURCE Phantom Neuro Inc.